第一三共、エンハーツが中国でHER2陽性胃がん二次治療に承認──DESTINY-Gastric04に基づく
ENHERTU (trastuzumab deruxtecan) approved in China for second-line HER2-positive gastric cancer based on DESTINY-Gastric04
stellanews.life/technology/8...
#GastricCancer #HER2 #ENHERTU #AntibodyDrugConjugate #DESTINYGastric04
ENHERTU (trastuzumab deruxtecan) approved in China for second-line HER2-positive gastric cancer based on DESTINY-Gastric04
stellanews.life/technology/8...
#GastricCancer #HER2 #ENHERTU #AntibodyDrugConjugate #DESTINYGastric04
第一三共、エンハーツが中国でHER2陽性胃がん二次治療に承認──DESTINY-Gastric04に基づく | STELLANEWS.LIFE
STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見
stellanews.life
February 12, 2026 at 2:39 PM
第一三共、エンハーツが中国でHER2陽性胃がん二次治療に承認──DESTINY-Gastric04に基づく
ENHERTU (trastuzumab deruxtecan) approved in China for second-line HER2-positive gastric cancer based on DESTINY-Gastric04
stellanews.life/technology/8...
#GastricCancer #HER2 #ENHERTU #AntibodyDrugConjugate #DESTINYGastric04
ENHERTU (trastuzumab deruxtecan) approved in China for second-line HER2-positive gastric cancer based on DESTINY-Gastric04
stellanews.life/technology/8...
#GastricCancer #HER2 #ENHERTU #AntibodyDrugConjugate #DESTINYGastric04